HBW-012462
/ Hyperway Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 15, 2025
Haibo Pharmaceuticals officially submits IND application for HBW-012462, a Pan-KRAS inhibitor with broad-spectrum inhibition of KRAS core mutations
(bydrug.pharmcube.com)
New trial • Oncology
1 to 1
Of
1
Go to page
1